Filing search / Oncorus, Inc. / "Recruitment"

8-K

EX-99.1

ONCR Oncorus, Inc.

30 Nov 22

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

7:07am

and elicited tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple

8-K

ONCR Oncorus, Inc.

30 Nov 22

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

7:07am

in tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple

10-K

tcxixu 0n72snmzowq2

10 Mar 21

Annual report

4:12pm

424B4

wdtje6le6m0

12 Feb 21

Prospectus supplement with pricing info

4:23pm

DRS

hm1iw n4z

28 Jan 21

Draft registration statement

12:00am

10-Q

ylzhhtu

12 Nov 20

Quarterly report

8:01am

424B4

blxn2x112o30b4o5x

2 Oct 20

Prospectus supplement with pricing info

12:00am

S-1

7ve5g 0erub

11 Sep 20

IPO registration

4:49pm

DRS/A

zlbfu mjdbw

26 Aug 20

Draft registration statement (amended)

12:00am

DRS/A

4f29h3ns3nqmf6h5x6p

29 Jul 20

Draft registration statement (amended)

12:00am

DRS/A

dk7s2yeo4p

20 Dec 19

Draft registration statement (amended)

12:00am

DRS

1qs1un nt2

31 Oct 19

Draft registration statement

12:00am